GB1340032A - Biologically active ketones - Google Patents
Biologically active ketonesInfo
- Publication number
- GB1340032A GB1340032A GB5923169A GB1340032DA GB1340032A GB 1340032 A GB1340032 A GB 1340032A GB 5923169 A GB5923169 A GB 5923169A GB 1340032D A GB1340032D A GB 1340032DA GB 1340032 A GB1340032 A GB 1340032A
- Authority
- GB
- United Kingdom
- Prior art keywords
- formula
- compound
- dec
- reacted
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000002576 ketones Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 6
- 150000003839 salts Chemical class 0.000 abstract 2
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 abstract 2
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 229940005513 antidepressants Drugs 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 230000026030 halogenation Effects 0.000 abstract 1
- 238000005658 halogenation reaction Methods 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000020477 pH reduction Effects 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/80—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen
- C07C49/807—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen all halogen atoms bound to the ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1340032 m - Halo - α - t - butylaminopropiophenones WELLCOME FOUNDATION Ltd (Burroughs Wellcome & Co (USA) Inc) 3 Dec 1970 [4 Dec 1969] 59231/69 Heading C2C Novel compounds of Formula I and acid addition salts thereof wherein X is Cl or F are prepared by one of the following methods: (a) a compound of Formula Va wherein Hal is Cl, Br or I is reacted with t-butyl amine; (b) a compound of formula is oxidized or (c) a compound of formula wherein R<SP>1</SP> is C 1-3 alkoxy is reacted with t-butylamine and in all eases optionally followed by salt formation. Intermediates of Formula Va above are prepared by halogenation of the ketones of formula obtained by reaction of the appropriate halophenylnitrile with ethyl magnesium bromide followed by acidification. Pharmaceutical compositions in conventional forms for oral, rectal or parenteral administration and having antidepressant activity comprise an above novel compound and a carrier or diluent. Treatment of depression in non- human animals comprises administration of the above novel compounds or compositions.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB5923169 | 1969-12-04 | ||
| CA213,916A CA977778A (en) | 1969-12-04 | 1974-11-15 | Intermediates for biologically active ketones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1340032A true GB1340032A (en) | 1973-12-05 |
Family
ID=25667756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB5923169A Expired GB1340032A (en) | 1969-12-04 | 1969-12-04 | Biologically active ketones |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB1340032A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2473884A1 (en) * | 1980-01-21 | 1981-07-24 | Wellcome Found | ASSOCIATIONS OF A HALOGENO-PROPIOPHENONE AND A DIAZEPINE, TRANQUILIZING MEDICAMENTS CONTAINING SUCH ASSOCIATIONS, AND THEIR PREPARATION |
| EP0118036A1 (en) * | 1983-02-03 | 1984-09-12 | The Wellcome Foundation Limited | Biologically active ketone derivative, preparation and use |
| US7884136B2 (en) | 2005-06-27 | 2011-02-08 | Biovail Laboratories International S.R.L. | Modified-release formulations of a bupropion salt |
-
1969
- 1969-12-04 GB GB5923169A patent/GB1340032A/en not_active Expired
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2473884A1 (en) * | 1980-01-21 | 1981-07-24 | Wellcome Found | ASSOCIATIONS OF A HALOGENO-PROPIOPHENONE AND A DIAZEPINE, TRANQUILIZING MEDICAMENTS CONTAINING SUCH ASSOCIATIONS, AND THEIR PREPARATION |
| US4571395A (en) * | 1980-01-21 | 1986-02-18 | Burroughs Wellcome Co. | Lorazepam and bupropion, compositions and methods |
| US4798826A (en) * | 1980-01-21 | 1989-01-17 | Burroughs Wellcome Co. | Benzodiazepine tranquilizer combinations and the use thereof |
| EP0118036A1 (en) * | 1983-02-03 | 1984-09-12 | The Wellcome Foundation Limited | Biologically active ketone derivative, preparation and use |
| US7884136B2 (en) | 2005-06-27 | 2011-02-08 | Biovail Laboratories International S.R.L. | Modified-release formulations of a bupropion salt |
| US8932628B2 (en) | 2005-06-27 | 2015-01-13 | Valeant International Bermuda | Modified release formulations of a bupropion salt |
| US9504640B2 (en) | 2005-06-27 | 2016-11-29 | Valeant Pharmaceuticals Luxembourg S.Á.R.L. | Modified release formulations of a bupropion salt |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB1526331A (en) | Phthalanes | |
| GB1301754A (en) | ||
| GB1313689A (en) | Quinoxaline derivatives | |
| GB1132082A (en) | The manufacture of pyrimidine derivatives | |
| GB1345880A (en) | Pyridazine derivatives | |
| GB1262965A (en) | Butyrophenones | |
| GB1369249A (en) | Amines the preparation thereof and their use in pharmaceutical compositions | |
| GB1467110A (en) | 4-phenyl-5-oxo-heptenoic acids | |
| GB1513320A (en) | N-propargyl-2-phenylamino-2-imidazolines | |
| GB1340032A (en) | Biologically active ketones | |
| GB1321424A (en) | N-phenyl-n-disubstituted aminoalkyl-2-amino indanes | |
| GB1373367A (en) | Hydroxyalkyl substituted 4,5-dihydropyridazin 2h-3-ones | |
| GB1392584A (en) | Anilides and the production thereof | |
| GB1448781A (en) | N- omega-amino- alkylaniline compounds | |
| GB1463369A (en) | 2-azacycloalkylmethyl substituted phenyl carbinols and ketones | |
| GB1245549A (en) | (thienylideneamino)oxy-alkanoic acid and derivatives thereof | |
| GB1473971A (en) | 3-hydroxy-5,6-benzomorphinan derivatives | |
| GB1531041A (en) | Substituted haloacetophenone oximes | |
| GB1343833A (en) | Substituted hexahydroazepines | |
| GB1295040A (en) | ||
| GB1472344A (en) | Methylene dibenzocycloheptanes | |
| SE7408868L (en) | ||
| GB1495680A (en) | 1-(2-benzoylphenoxy)-2-hydroxy-3-aminopropanes | |
| GB1470743A (en) | Cyclopropylmethylamine derivatives | |
| GB1133406A (en) | Substituted 1-amino phthalazines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 416 | Proceeding under section 16 patents act 1949 | ||
| PS | Patent sealed [section 19, patents act 1949] | ||
| PCNP | Patent ceased through non-payment of renewal fee |